Dassault Systèmes SE DSY
ParisApplication softwareFinancials to Sep 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| €B | Dec 31 | Sep 30 |
|---|---|---|
| Cash | 4.1 | 3.8 |
| Securities | 0.0 | 0.0 |
| Debt | 2.6 | 2.8 |
| Net cash | 1.5 | 1.0 |
| Equity | 8.8 | 9.7 |
- Debt / EBITDA
- 1.33×
- Debt / equity
- 0.29×
- Leases (12/31/25)
- €574M
- Diluted shares
- 1,325M
- Book value / share
- €7.30
- Price / book
- 3.5×
- Net cash / share
- €0.79
- Market cap
- €33.4B
- Enterprise value
- €32.4B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 quarters |
|---|---|---|---|
| Revenue growth | 6.3% | +6.5 pts | |
| Operating margin | 20.9% | +0.3 pts | |
| FCF margin | 18.7% | +7.9 pts | |
| Capex / revenue | 2.6% | +0.6 pts | |
| 3DEXPERIENCE software revenue growth | +25% | +9 pts | |
| Cloud software revenue growth | +14% | +6 pts | |
| Industrial Innovation software revenue growth | +5% | -4 pts | |
| Mainstream Innovation software revenue growth | +8% | +4 pts | |
| Life Sciences software revenue growth | +1% | +4 pts |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About DSY
Dassault Systèmes sells software for product design, simulation, manufacturing and clinical development. Its 2025 IFRS software revenue was EUR5.641 billion: 55.6% Industrial Innovation, 25.3% Mainstream Innovation and 19.2% Life Sciences.
- Data Workflow Lockin
Product models, engineering changes and manufacturing processes sit in connected software workflows.
- Suite Bundling
CAD, simulation, PLM/data and manufacturing applications can be adopted as a connected suite, but Dassault does not disclose attach rates and customers often retain heterogeneous best-of-breed toolchains.
- Switching Costs General
Engineer training, accumulated CAD models and downstream integrations raise switching costs, but SMB customers can change tools faster than large enterprises and the company does not disclose product-line retention.
- Data Workflow Lockin
Clinical platforms connect patient, site and study-data workflows; integrations and active multi-year trials make in-flight switching risky, although the fragmented market and multi-vendor stacks limit durable platform control.
- Sep 24, 2026
SYSTRA and Dassault began a transport-infrastructure virtual-twin collaboration, extending the platform into rail engineering. No contract value or sales contribution was announced.
- Sep 10, 2026
Centric introduced its unified AI platform for product decisions, extending automation inside design, sourcing and retail workflows; future paid adoption will determine its commercial value.
- Jul 23, 2026
Dassault agreed to acquire ArisGlobal for USD1.8 billion in cash plus up to USD200 million of milestone payments, adding safety and regulatory software if the transaction receives approval.
- Jul 23, 2026
Q2 Life Sciences software sales fell 4% at constant currency, weakening expansion despite new CRO and pharmaceutical contracts.
- Feb 21, 2026
Pascal Daloz also became chairman after Bernard Charlès stepped down, concentrating operating leadership and board leadership in one executive.
Ownership
Go deeper on DSY
- Compare stock research toolsFundamentals, valuation and screening platforms for DSY.19 tools
- See DSY's price chartNo price chart here yet. See price history and indicators.17 tools
- Read DSY's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2016–25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share (€) | |||||||||||||
| Revenue | 2.37 | 2.50 | 2.67 | 3.05 | 3.37 | 3.65 | 4.25 | 4.45 | 4.66 | 4.69 | 4.75 | +7.9%/yr | |
| Cash flow | 0.48 | 0.58 | 0.69 | 0.90 | 0.94 | 1.21 | 1.14 | 1.17 | 1.24 | 1.23 | 1.41 | +10.9%/yr | |
| Earnings | 0.35 | 0.40 | 0.44 | 0.47 | 0.37 | 0.58 | 0.70 | 0.79 | 0.90 | 0.90 | 1.01 | +11.2%/yr | |
| Free cash flow | 0.44 | 0.51 | 0.63 | 0.83 | 0.84 | 1.13 | 1.05 | 1.06 | 1.10 | 1.11 | 1.30 | +10.8%/yr | |
| Capex | 0.04 | 0.07 | 0.06 | 0.07 | 0.10 | 0.08 | 0.10 | 0.11 | 0.15 | 0.12 | 0.11 | +11.9%/yr | |
| Dividends | 0.08 | 0.04 | 0.03 | 0.13 | 0.14 | 0.11 | 0.17 | 0.21 | 0.23 | 0.26 | 0.27 | +14.2%/yr | |
| Book value | 3.00 | 3.09 | 3.50 | 3.96 | 3.83 | 4.65 | 5.49 | 5.86 | 6.80 | 6.62 | 7.30 | +9.2%/yr | |
| Diluted shares (M) | 1,287 | 1,292 | 1,304 | 1,316 | 1,321 | 1,332 | 1,333 | 1,337 | 1,333 | 1,329 | 1,325 | +0.4%/yr | |
| Totals (€B) | |||||||||||||
| Revenue | 3.1 | 3.2 | 3.5 | 4.0 | 4.5 | 4.9 | 5.7 | 6.0 | 6.2 | 6.2 | 6.3 | +8.2%/yr | |
| Operating income | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 1.0 | 1.3 | 1.2 | 1.4 | 1.4 | 1.5 | +8.1%/yr | |
| Net income | 0.4 | 0.5 | 0.6 | 0.6 | 0.5 | 0.8 | 0.9 | 1.1 | 1.2 | 1.2 | 1.3 | +11.6%/yr | |
| Free cash flow | 0.6 | 0.7 | 0.8 | 1.1 | 1.1 | 1.5 | 1.4 | 1.4 | 1.5 | 1.5 | 1.7 | +11.2%/yr | |
| Dividends | 0.1 | 0.1 | 0.0 | 0.2 | 0.2 | 0.1 | 0.2 | 0.3 | 0.3 | 0.3 | 0.4 | +14.7%/yr | |
| Net cash | 1.5 | 1.5 | 1.8 | -2.7 | -2.0 | -0.9 | -0.2 | 0.6 | 1.5 | 1.5 | 1.0 | +€0.0B | |
| Margins & returns (%) | |||||||||||||
| Operating margin | 22.0 | 22.6 | 22.1 | 20.2 | 15.0 | 21.0 | 23.0 | 20.9 | 21.9 | 21.7 | 24.4 | -0.3 pts | |
| Net margin | 14.6 | 16.1 | 16.4 | 15.3 | 11.0 | 15.9 | 16.4 | 17.7 | 19.3 | 19.2 | 21.3 | +4.5 pts | |
| FCF margin | 18.5 | 20.5 | 23.8 | 27.1 | 25.0 | 31.1 | 24.6 | 23.9 | 23.6 | 23.6 | 27.3 | +5.1 pts | |
| ROIC | 23.1 | 23.4 | 22.7 | 8.4 | 7.7 | 11.7 | 14.0 | 13.9 | 14.5 | 15.1 | 14.5 | -7.9 pts | |
| Return on equity | 11.6 | 13.0 | 12.5 | 11.8 | 9.7 | 12.5 | 12.7 | 13.4 | 13.2 | 13.6 | 13.9 | +2.0 pts | |
| R&D % of revenue | 17.7 | 17.9 | 18.1 | 18.4 | 21.0 | 19.5 | 19.2 | 20.6 | 20.7 | 21.2 | 20.5 | +3.5 pts | |
| Stock pay % of revenue | 2.3 | 2.9 | 2.4 | 2.9 | 4.0 | 3.5 | 2.9 | 3.1 | 3.1 | 2.8 | – | +0.5 pts | |
| Capex % of revenue | 1.9 | 2.6 | 2.1 | 2.4 | 2.9 | 2.1 | 2.3 | 2.4 | 3.1 | 2.6 | 2.2 | +0.7 pts | |
Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- durable
- Trajectory
- stable
- Pricing power
- moderate
- Industrial Innovation55.6%2 claims
- Mainstream Innovation25.3%1 claim
- Life Sciences19.2%1 claim
Moat claims
- Applies to
- Industrial Innovation
- Confidence
- Durability
- durable
- Trajectory
- stableas of Oct 6, 2026
Product models, engineering changes and manufacturing processes sit in connected software workflows. Replacing the platform means converting historical data, reconnecting tools and suppliers, and retraining teams. Volkswagen’s cloud standardization and long-running engineering programs support this advantage, although customers can retain multiple CAD systems.
Q2 Industrial Innovation software revenue grew 5% and cloud platform adoption increased, supporting customer persistence despite weak European auto demand.
- 3DEXPERIENCE software revenue growth+25%
- Cloud software revenue growth+14%
- Industrial Innovation software revenue growth+5%
- Recurring software revenue share84.0%-2.0 pts
- Annual Run Rate€4.5B
- Customer push for multi-CAD interoperability and open standards
- Cloud-native competitors reducing deployment friction
- Cyclical industrial capex (auto/aerospace) impacting spend
- Complexity or platform fatigue driving best-of-breed point-solution adoption
- SourceSYSTRA and Dassault Systèmes transport-infrastructure virtual-twin collaborationSep 24, 2026
- SourceDassault Systemes and Volkswagen Group implement the 3DEXPERIENCE platformFeb 4, 2025
- SourceDassault Systèmes 2025 Universal Registration DocumentMar 31, 2026
- NewsDassault Systemes and UK Fusion Energy expand the STEP plant-information platformJun 29, 2026
- Applies to
- Industrial Innovation
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 6, 2026
CAD, simulation, PLM/data and manufacturing applications can be adopted as a connected suite, but Dassault does not disclose attach rates and customers often retain heterogeneous best-of-breed toolchains.
Q2 platform software revenue grew 14% at constant currency, but the company gives no product attach rate to show whether suite purchases are becoming harder to replace.
- 3DEXPERIENCE software revenue growth+25%
- Cloud software revenue growth+14%
- Industrial Innovation software revenue growth+5%
- Recurring software revenue share84.0%-2.0 pts
- Annual Run Rate€4.5B
- Customers selectively unbundle into specialist tools
- Bundling discounts compress realized pricing
- SourceDassault Systèmes H1 2026 resultsJul 23, 2026
- Applies to
- Mainstream Innovation
- Confidence
- Durability
- medium
- Trajectory
- stableas of Oct 6, 2026
Engineer training, accumulated CAD models and downstream integrations raise switching costs, but SMB customers can change tools faster than large enterprises and the company does not disclose product-line retention.
Q2 Mainstream Innovation software revenue grew 8% with double-digit SOLIDWORKS unit growth, supporting adoption; no product renewal rate establishes stronger switching costs.
- Cloud software revenue growth+14%
- Mainstream Innovation software revenue growth+8%
- Recurring software revenue share84.0%-2.0 pts
- Annual Run Rate€4.5B
- Cloud-native CAD tools lowering onboarding and switching friction
- Price competition and discounting in SMB
- Greater use of neutral interchange formats reducing lock-in
- SourceCentric Software launches Centric AI for product decisionsSep 10, 2026
- SourceDassault Systèmes H1 2026 resultsJul 23, 2026
- Applies to
- Life Sciences
- Confidence
- Durability
- medium
- Trajectory
- narrowingas of Oct 6, 2026
Clinical platforms connect patient, site and study-data workflows; integrations and active multi-year trials make in-flight switching risky, although the fragmented market and multi-vendor stacks limit durable platform control.
Life Sciences software revenue fell 4% in Q2 after several weak quarters. Expanded pharma and CRO contracts support existing workflows, but study volumes and competition weaken expansion.
- Cloud software revenue growth+14%
- Life Sciences software revenue growth+1%
- Recurring software revenue share84.0%-2.0 pts
- Annual Run Rate€4.5B
- Trial-start slowdowns reducing usage and expansion
- Customers adopting multi-vendor clinical stacks
- Data portability demands and integration standards reducing lock-in
- SourceWorldwide Clinical Trials and Medidata strategic partnershipApr 23, 2026
- SourceMedidata extends collaboration with SanofiOct 23, 2025
- SourceDassault Systèmes 2025 Universal Registration DocumentMar 31, 2026
- SourceDassault Systèmes Q2 2026 resultsJul 23, 2026
Profile change log
- Oct 6, 2026 · business change
Dassault wrote down GEOVIA goodwill by EUR32.9 million as Russian mining prospects weakened, reducing expected value in its mining software business.
- Oct 6, 2026 · business change
France’s Supreme Court rejected acquisition-financing tax appeals, leading to a EUR144.9 million tax charge that reduced 2022 profit.
- Oct 6, 2026 · business change
Dassault acquired Medidata, entering clinical trial software at scale and adding acquisition debt. The deal changes the scope of the financial record from late 2019.
- Oct 6, 2026 · business change
SYSTRA and Dassault began a transport-infrastructure virtual-twin collaboration, extending the platform into rail engineering. No contract value or sales contribution was announced.
- Oct 6, 2026 · business change
Centric introduced its unified AI platform for product decisions, extending automation inside design, sourcing and retail workflows; future paid adoption will determine its commercial value.
- Oct 6, 2026 · business change
Q2 Life Sciences software sales fell 4% at constant currency, weakening expansion despite new CRO and pharmaceutical contracts.
- Oct 6, 2026 · business change
Dassault agreed to acquire ArisGlobal for USD1.8 billion in cash plus up to USD200 million of milestone payments, adding safety and regulatory software if the transaction receives approval.
- Oct 6, 2026 · business change
Pascal Daloz also became chairman after Bernard Charlès stepped down, concentrating operating leadership and board leadership in one executive.
- Oct 6, 2026 · analyst revision
The segment mix now uses full-year 2025 IFRS software sales, replacing the H1 2026 adjusted mix. Current growth supports industrial and mainstream switching costs, while declining clinical sales weaken Life Sciences expansion. Competition includes Siemens-owned Altair and Synopsys-owned Ansys.
Industry & peers
Peer map
Hover a point for its values; click a peer to compare. Dashed lines: industry medians.
Product design and lifecycle software
Commercial software for mechanical product design, engineering simulation, manufacturing planning and product data and process management. Covers large manufacturers, engineering teams and consumer-product brands; excludes clinical trial systems, general ERP and physical engineering equipment.
- Dassault Systèmes
- Siemens Digital Industries Software, including Altair
- PTC
- Autodesk
- Ansys, now part of Synopsys
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| DSY | 77 | – | 24.4% | |
| Industry median | 31 | 78 | 75.8% | 19.9% |
| Sector median | 77 | 75 | 64.7% | 23.8% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- More complex products need connected mechanical design, software, simulation and manufacturing data, expanding the work performed inside engineering platforms.
- Electric vehicles, aerospace programs and industrial equipment require new designs and process changes, but contract timing follows customers’ capital budgets.
- Cloud deployment can widen collaboration across suppliers and small engineering teams while reducing local infrastructure needs.
- Industrial AI and virtual twins can create new paid uses for existing engineering data; commercial uptake depends on measurable customer savings.
- Product traceability, cybersecurity and environmental requirements support spending on controlled lifecycle records.
- Weak auto and industrial investment delays new licenses and large platform decisions even when support contracts renew.
- Siemens, PTC, Autodesk and specialist tools contest new projects; open formats and customer integrations can reduce dependence on one suite.
- Moving to subscriptions changes revenue recognition and can hide weak new customer demand behind a larger recurring share.
- Security breaches or cloud outages can disrupt engineering work and deter adoption in sensitive defense and industrial programs.
- A stronger euro or U.S. dollar reduces translated international revenue for suppliers reporting in that currency. Higher rates and tariffs can constrain manufacturers' investment budgets; cloud hosting and AI compute costs can reduce supplier margins.
Bulls & bears
Can Dassault turn cloud and platform adoption into broad recurring growth while restoring clinical software demand and integrating ArisGlobal?
Arguments
What to watch
- 13DEXPERIENCE and cloud software revenue growth at constant currency
- 2Mainstream and Life Sciences software revenue, SOLIDWORKS unit growth and clinical bookings
- 3Annual Run Rate, reported operating cash flow and cash use for ArisGlobal
Next check: Q3 results on October 28, 2026 and Capital Markets Day on November 17, 2026; check for ArisGlobal closing approval and revised targets.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 77/100 by <a href="https://www.findmymoat.com/stocks/XPAR:DSY">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.